Our executive management team sets the strategic direction for Sanos and ensures we stay focused on our scientific expertise, operational excellence, and world-class team.
With deep experience across clinical research, healthcare, and life sciences, they lead our mission to advance medical innovation through specialized, expert-driven CRO services.
Jeppe is the CEO of NBCD, as well as the Group CEO of Sanos (the parent company of NBCD, Neuroscios, Blueskin and Sanos Clinic).
Jeppe holds a master’s in Pharmaceutical Science (M.Sc. Pharm) from University of Copenhagen, Denmark, and joined Nordic Bioscience in 2007 as a CRA. In 2010 he became Head of Clinical Development in 2010, and in 2014 he transitioned into his position as the CEO of NBCD.
Jeppe has been involved on an operational and executive level in numerous clinical studies with more than 18,000 patients within various therapeutic fields but primarily within osteoporosis and osteoarthritis leading to market approved drugs in both indications. Jeppe has been spearheading the journey of building Sanos from a handful of people back in 2007 to the 250 employees’ midsize multi-niche CRO company of 2025.
With his history of success in building and growing organizations, his strong expertise from both CRO and Investigator perspective, and his in-depth project leadership in clinical development, he has an ability to identify market trends and conceptualize strategies with an aim of innovation to improve work and business processes.
Asger is the Chief Scientific Officer of Sanos and is an internationally renowned expert in musculoskeletal drug development, pain, and clinical trial design. He joined NBCD in 2013, and assumed the position as Medical Director in 2014. In 2021, he transitioned into his current position as group CSO.
Asger holds a PhD for the University of Southern Denmark, and a master’s in Pharmaceutical Science (M.Sc. Pharm) from University of Copenhagen, and has held several leading positions in pharma and clinical research organizations within regulatory affairs, medical affairs, and clinical science. He has published more than 50 peer-reviewed papers, primarily on musculoskeletal clinical science, in high-ranking journals. Asger has played key roles in the design and conduct of landmark trials, including the sprifermin FORWARD trial published in JAMA in 2019, and is a frequent speaker at OARSI, EULAR, and ACR conferences, where more than 50 original abstracts have been presented, in addition to invited speaker sessions on musculoskeletal trial design and placebo response mitigation.
As Chief Scientific Officer, Asger currently leads the scientific and medical affairs activities of Sanos and the subsidiaries CROs. As chief scientist, Asger was the primary responsible person for the design and conduct of a long series of global trials totaling approximately 18,000 study participants evaluating experimental treatments primarily within musculoskeletal conditions.
Asger is actively researching in the fields of arthritis and osteoporosis, with a particular focus on optimizing clinical trial methodology and outcome.
Casper is the Chief Commercial Officer of Sanos and is responsible for business development as well as the marketing efforts across the four business units.
Casper holds a master’s in Pharmaceutical Science (M.Sc. Pharm) from University of Copenhagen, Denmark, and joined NBCD in 2016 as Clinical Trial Leader. In 2019, he transitioned into the position as Business Development Director and in 2022 he was appointed Chief Commercial Officer of Sanos.
Casper has a longstanding background (20+ years) working with clinical operations and strategic business development in various pharma, biotech and CRO companies. Over the years, Casper has gained unique insight to the different actors of the life-science industry, which has led to a profound understanding of current and future Sanos partners resulting in strong strategic and scientific alliances.
Casper has dedicated most of his professional career to the fields of dermatology and musculoskeletal indications – the latter through a deep specialization within osteoarthritis.
Sara is the Chief Operating Officer of Sanos and has been with the company since 2011. She holds a master’s in Pharmaceutical Science (M.Sc. Pharm) from University of Copenhagen, Denmark, and started her career in NBCD as a Clinical Research Associate.
Sara has held many positions within Study Operations through the years. Before shifting her focus to the operational and compliance management of the organization, Sara was involved in numerous clinical studies with a total of more than 18,000 patients within the musculoskeletal area.
Sara has headed the successful expansion of the Clinical Operations Department and the integration of Sanos Quality Management System, including implementation of Risk-Based Monitoring and various computerized systems over the years. Most recently she has played a strong role in the expansion of Sanos’ operating units through acquisitions and building on existing organisations, while supporting the business units in running smooth organizations with very low staff turnover, while simultaneously ensuring successful conduction of the clinical trials.
Jakob is the Chief Financial Officer of Sanos, and has been with the company since the beginning of 2024.
Jakob holds a bachelor’s in Accounting (HD-R) and a master’s of Business Administration and Economics (cand. merc.) from Aarhus University, Denmark. Jakob is a seasoned financial executive with over 20 years of experience in international biotech and life science companies. Jakob joined Sanos Group from Unibio A/S, a leading sustainable protein company, where he served as CFO since 2018. Before that, Jakob was CFO at BioPorto A/S, a Danish Nasdaq-listed Biotech company, and US CFO of Origio A/S, a global provider of products for in vitro fertilization. Jakob started his career with 10 years in accounting at EY and Investment Banking at Svenska Handelsbanken.
Driven by a passion for healthcare and with a proven track record as a CFO in both Denmark and the USA, Jakob brings a wealth of expertise in financial management, operations, business development, investor relations and capital markets.
Christoffer is the Chief Innovation Officer of Sanos Group and has been with the company since 2020. He holds a master’s in Pharmaceutical Science (M.Sc. Pharm) from University of Copenhagen, Denmark and started his career as a Clinical Research Associate in 2001.
Before joining NBCD, Christoffer has held various positions within clinical operations and data management in both pharma, biotech and CRO; thereby gaining experience from phase 1 to 4 including numerous inspections from FDA and EMA.
Christoffer’s main focus is seeing the bigger picture and implementing solutions that enhances the performance across all involved team members from synopsis to final study report.
Mickey is the Chief Information Officer at Sanos and has been with the company since Februar 2021. He holds multiple certifications including GIAC Information Security Professional (GISP from SANS Institute), Pentest+, CySA+, Security+ (CompTIA), VCPD55-DCV (VMware Certified Professional) and ITIL Foundation.
Mickey joined Sanos as an IT-Consultant to assist with the IT-carveout during a demerger from our parent branch Nordic Bioscience. Later on, he accepted the position as CIO and thus relocating from Dubai, where he resided and worked for almost 7 years. He has more than 19 years of IT experience and has worked in various industries such as fitness/welness, various government entities, and CRO’s like NBCD.
As CIO, Mickey is responsible for the Cyber Security program, IT infrastructure, and ensuring the Governance and compliance for the entire Sanos.
Gunnleyg is Global HR Director at Sanos. She has led the company’s people agenda and advancing its people and culture strategy since 2022. Her work focuses on enabling growth, enhancing the employee experience, and aligning HR with business goals
She holds a master’s degree in Strategy and Management from Aarhus School of Business and brings over 15 years of HR experience, including 12 years in the financial sector. Her expertise spans leadership development, organizational design, talent acquisition, employee journey design, and driving operational excellence through digitalization.